A mild variant of cystic fibrosis

Thorax

Volumn 51, Issue SUPPL. 2, 1996, Pages

  Alton, Eric W F W ^a  

^a NATIONAL HEART AND LUNG INSTITUTE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CFTR PROTEIN, HUMAN; TRANSMEMBRANE CONDUCTANCE REGULATOR;

CYSTIC FIBROSIS; GENETICS; HUMAN; LUNG; MUTATION; PATHOPHYSIOLOGY; REVIEW;

CYSTIC FIBROSIS; CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR; HUMANS; LUNG; MUTATION;

EID: 1842509752     PISSN: 00406376     EISSN: None     Source Type: Journal    
DOI: 10.1136/thx.51.Suppl_2.S51     Document Type: Article

References (18)

1. Gan K-H, Veeze HJ, van den Ouweland AMW, Halley DJJ, Scheffer H, van der Hout A, et al. A cystic fibrosis mutation associated with mild lung disease N Engl J Med 1995;333:95-9.
2. Riordan JR, Kommens JM, Kerem BS, Alon N, Rozmahel R, Grzelczak Z, et al. Identification of the cystic fibrosis gene: cloning and characterisation of complementary DNA. Science 1989;245:1066-73.
3. Welsh MJ. Electrolyte transport by airway epithelia. Physiol Rev 1987; 67:1143-84.
4. Knowles M, Gatzy J, Boucher R. Increased biolectric potential difference across respiratory epithelia in cystic fibrosis. N Engl J Med 1981;305: 1489-95.
5. Stutts MJ, Canessa CM, Olsen JC, Hamrick M, Cohn JA, Rossier BC, et al. CFTR as a cAMP-dependent regulator of sodium channels. Science 1995;269:847-50.
6. Imundo L, Barasch J, Prince A, Al-Awqati Q. Cystic fibrosis epithelial cells have a receptor for pathogenic bacteria on their apical surface. Proc Natl Acad Sci USA 1995;92: 3019-23.
7. Pier GB, Grout M, Zaidi TS, Olsen JC, Johnson LG, Yankaskas JR, et al. Role of mutant CFTR in hypersusceptibility of cystic fibrosis patients to lung infections. Science 1996;271:64-7.
8. Smith JJ, Travis SM, Greenherg HP, Welsh MJ. Cystic fibrosis airway epithelia fail to kill bacteria because of abnormal airway surface fluid. Cell 1996;85:229-36.
9. Welsh MJ, Smith AE. Molecular mechanisms of CFTR chloride channel dysfunction in cystic fibrosis. Cell 1993;73:1251-4.
10. Yang Y, Janich S, Cohn JA, Wilson JM. The common variant of cystic fibrosis transmembrane conductance regulator is recognised by hsp 70 and degraded in a pre-Golgi nonlysosomal compartment. Proc Natl Acad Sci USA 1993;90:9480-4.
11. Sheppard DN, Rich DP, Ostedgaard LS, Gregory RJ, Smith AE, Welsh MJ. Mutations in CFTR associated with mild-disease-form C1-channels with altered pore properties. Nature 1993;362:160-4.
12. Kerem E, Corey M, Kerem BS, Rommens J, Markiewicz D, Levison H, et al. The relation between genotype and phenotype in cystic fibrosis analysis of the most common mutation. N Engl J Med 1990; 323:1517-22.
13. Fitzgerald O, Van Asperen P, Henry R, Waters D, Freelander M, Wilson M, et al. Delayed diagnosis of cystic fibrosis in children with a rare genotype (delta F508/R117H). J Paediatr Child Health 1995;31: 168-71.
14. Anonymous. Correlation between genotype and phenotype in patients with cystic fibrosis. N Engl J Med 1993;329:1308-13.
15. Crawford I, Maloney PC, Zeitlin PL, Guggino WB, Hyde SC, Turley H, et al. Immunocytochemical localization of the cystic fibrosis gene product CFTR. Proc Natl Acad Sci USA 1991;88:9262-6.
16. Baxter P, Goldhill J, Hardcastle J, Hardcastle PT, Taylor CJ. Enhanced intestinal glucose and alanine transport in cystic fibrosis. Gut 1990; 31:817-20.
17. Veeze HJ, Halley DJJ, Bijman J, de Jongste JC, de Jonge HR, Sinaasappel M. Determinants of mild clinical symptoms in cystic fibrosis patients: residual chloride secretion measured in rectal biopsies in relation to the genotype. J Clin Invest 1994;93:461-6.
18. Dorin JR, Farley R, Webb S, Smith SN, Farini E, Delaney SJ, et al. A demonstration using mouse models that successful gene therapy for cystic fibrosis requires only partial gene correction. Gene Therapy 1996 (in press).